Format

Send to

Choose Destination
See comment in PubMed Commons below
Ther Clin Risk Manag. 2006 Dec;2(4):389-400.

Infliximab (Remicade) in the treatment of psoriatic arthritis.

Author information

1
Seattle Rheumatology Associates, Division of Rheumatology Research, Swedish Medical Center, University of Washington School of Medicine Seattle, WA, USA.

Abstract

Elucidation of the cellular immunopathology and cytokine profile of psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, has resulted in the development of a number of novel biologic therapies. Among these biologics, tumor necrosis factor-alpha (TNF-alpha) inhibitors have been used successfully to treat patients suffering from rheumatoid arthritis or psoriasis. The pivotal role of TNF-alpha in the pathogenesis and progression of PsA suggested that anti-TNF-alpha agents could be effective in controlling PsA. The results from two large, randomized, double-blind, placebo-controlled trials in patients with moderate to severe PsA indicated that the anti-TNF-inhibitor, infliximab, can control both the joint and skin manifestations of the disease. This review focuses on the clinical development of infliximab as a treatment for PsA. The development of other anti-TNF-alpha biologics is also discussed.

PMID:
18360651
PMCID:
PMC1936360
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center